Intraocular shunt manufacture

Information

  • Patent Grant
  • 10314743
  • Patent Number
    10,314,743
  • Date Filed
    Thursday, March 9, 2017
    7 years ago
  • Date Issued
    Tuesday, June 11, 2019
    5 years ago
Abstract
An intraocular shunt can be manufactured using a system that includes a liquid bath and a wire, which is moved through the bath. The wire can be moved through a first liquid bath to produce a first tubular layer of drug-infused gelatin. Further, the wire can be moved through a second liquid bath to produce a second tubular layer of drug-free gelatin. The first and second tubular layers can be dried on the wire in a humidity-controlled space, thereby manufacturing a drug-loaded gelatin shunt.
Description
BACKGROUND

Field


The invention generally relates to systems and methods for making gelatin shunts.


Description of the Related Art


Glaucoma is a disease of the eye that affects millions of people. Glaucoma is associated with an increase in intraocular pressure resulting either from a failure of a drainage system of an eye to adequately remove aqueous humor from an anterior chamber of the eye or overproduction of aqueous humor by a ciliary body in the eye. Build-up of aqueous humor and resulting intraocular pressure may result in irreversible damage to the optic nerve and the retina, which may lead to irreversible retinal damage and blindness.


Glaucoma may be treated in a number of different ways. One manner of treatment involves delivery of drugs such as beta-blockers or prostaglandins to the eye to either reduce production of aqueous humor or increase flow of aqueous humor from an anterior chamber of the eye. Glaucoma may also be treated by surgical intervention that involves placing a shunt in the eye to result in production of fluid flow pathways between an anterior chamber of an eye and various structures of the eye involved in aqueous humor drainage (e.g., Schlemm's canal, the sclera, or the subconjunctival space). Such fluid flow pathways allow for aqueous humor to exit the anterior chamber.


A problem with implantable shunts is that they are composed of a rigid material, e.g., stainless steel, that does not allow the shunt to react to movement of tissue surrounding the eye. Consequently, existing shunts have a tendency to move after implantation, affecting ability of the shunt to conduct fluid away from the anterior chamber of the eye. To prevent movement of the shunt after implantation, certain shunts are held in place in the eye by an anchor that extends from a body of the shunt and interacts with the surrounding tissue. Such anchors result in irritation and inflammation of the surrounding tissue. Further, implanting a rigid shunt may result in the shunt causing blunt trauma upon insertion into an eye, such as producing a cyclodialysis cleft, or separation of the ciliary body from the scleral spur, creating hypotony by allowing the uncontrolled escape of aqueous humor through the cleft into the suprachoroidal space.


To address the problems associated with shunts made of rigid material, people have begun to make shunts from flexible material, such as gelatin. See for example, Yu et al. (U.S. Pat. No. 6,544,249 and U.S. Patent Application Publication No. 2008/0108933). Gelatin shunts may be reactive to pressure, and thus can be implanted without the use of anchors. Consequently, gelatin shunts will maintain fluid flow away for an anterior 5 chamber of the eye after implantation without causing irritation or inflammation to the tissue surrounding the eye. Additionally, the flexibility of a gelatin shunt prevents it from causing blunt trauma upon insertion into an eye, and thus reduces or eliminates the risk of producing a cyclodialysis cleft.


However, there are numerous issues associated with making gelatin shunts. For example, it is difficult to control and manipulate liquid gelatin, which is important in order to produce a gelatin shunt with a uniform cross-section and uniform shape along a length of the implant. Additionally, there are challenges associated with the drying process that also make it difficult to produce a gelatin shunt with a uniform cross-section and uniform shape along a length of the implant.


SUMMARY

The invention generally provides systems and methods for making gelatin shunts. Particularly, systems and methods of the invention address and solve the above-described problems with manufacturing gelatin shunts.


Certain aspects of the invention address the problems of controlling and manipulating liquid gelatin. The invention recognizes that simply routing a wire through a temperature controlled gelatin bath is not sufficient to produce a gelatin shunt with a uniform cross-section and uniform shape along a length of the implant. Heated gelatin alone forms a skin layer on top of the gelatin. Pulling a wire through a gelatin bath alone results in the wire passing through the skin layer, which makes it impractical to control the gelatin uptake on the wire. The invention solves this aspect of the problem by adding a water layer on top of the gelatin. The water layer eliminates the skin effect, and allows for production of a uniform cone of gelatin upon pulling a wire through the gelatin and then the water layer. Where the gelatin cone intersects the water-air boundary, a spot forms. This spot is exposed to air, and gelatin from this spot is taken up the wire.


However, the invention also recognizes that more gelatin reaches the top of the water than can be taken up by the wire. This results in cast-off, which renders the cone, and thus the spot at the boundary layer, unstable, i.e., the gelatin deposit is inconsistent in diameter. To solve this aspect of the problem, the systems and methods of the invention use a plate having an aperture, which aperture controls the gelatin spot. The plate having the aperture is situated in the water layer, and with the aperture plate in place, the cone of gelatin that feeds the spot is consistent and yields a uniform uptake of gelatin onto the wire.


Other aspects of the invention address the problems associated with the drying process that also make it difficult to produce a gelatin shunt with a uniform cross-section and uniform shape along a length of the implant. As the water evaporates from the gelatin on the wire, the gelatin shrinks in diameter. However, the wire constrains the gelatin from shrinking axially. If humidity is left uncontrolled, an outer skin of the gelatin dries and hardens before the gelatin has completed shrinking. This results in non-uniform cross sections and shapes along the implant length. The invention recognizes that drying the gelatin on the wire in a humidity-controlled space produces a uniform implant along the length of the wire. One manner by which this is accomplished involves immersing the gelatin in an ultrasonic fog that keeps the outer skin of the gelatin hydrated as the internal volume of the gelatin shrinks.


Systems and methods of the invention incorporate these solutions to the above-described problems associated with manufacturing a gelatin shunt. Methods of the invention may involve moving a wire through a bath including a bottom layer of liquid gelatin and a top layer of water, thereby coating the wire with gelatin, moving the gelatin-coated wire through an aperture, and drying the gelatin on the wire in a humidity-controlled space, thereby manufacturing a gelatin shunt. The dried shunt includes a uniform shape and a uniform cross-section.


Movement of the wire may be controlled manually or mechanically. In certain embodiments, the moving wire is mechanically controlled, by for example, by a stepper motor. Any method for controlling humidity may be used with methods of the invention. In particular embodiments, the humidity is controlled by drying in the presence of an ultrasonic water fog. The aperture is generally located in the water layer, and the wire is preferably moved vertically through the bath, such that the gelatin-coated wire is vertical during the drying step. In certain embodiments, the manufactured shunt is sized and dimensioned to be an intraocular shunt.


In certain embodiments, the liquid gelatin may include a drug, and thus produces shunts that may be coated or impregnated with at least one pharmaceutical and/or biological agent or a combination thereof. Any pharmaceutical and/or biological agent or combination thereof may be used with shunts of the invention. The pharmaceutical and/or biological agent may be released over a short period of time (e.g., seconds) or may be released over longer periods of time (e.g., days, weeks, months, or even years). Exemplary agents include anti-mitotic pharmaceuticals such as Mitomycin-C or 5-Fluorouracil, anti-VEGF (such as Lucentis, Macugen, Avastin, VEGF or steroids). Exemplary agents are shown in Darouiche (U.S. Pat. Nos. 7,790,183; 6,719,991; 6,558,686; 6,162,487; 5,902,283; 5,853,745; and 5,624,704) and Yu et al. (U.S. Patent Application Ser. No. 2008/0108933). The content of each of these references is incorporated by reference herein its entirety.


Systems of the invention may include a motor, a wire operably coupled to the motor for movement of the wire, a temperature controllable bath, an aperture plate situated in a top portion of the bath, and an ultrasonic fogger, the system being configured such that the wire moves through the bath, through the aperture plate, and into the ultrasonic fogger. Generally, the wire initially moves down toward a bottom of the bath and then turns to move vertically out of the bath. From there, the wire moves through the aperture plate, and then the wire moves vertically through the ultrasonic fogger. Systems of the invention may also include a first camera positioned to view the wire as it moves through the aperture plate. Systems of the invention may also further include a second camera that includes software to measure the gelatin-coated wire as it passes into the fogger.


The bath may be filled with liquid gelatin and water. The liquid gelatin fills a bottom layer of the bath and the water fills a top layer of bath. In certain embodiments, the liquid gelatin includes a drug.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic showing an embodiment of a system of the invention.



FIG. 2 is a schematic showing a magnified view of FIG. 1, focusing on the wheels that carry the wire.



FIG. 3 is an image of the aperture plate with a wire running through the aperture.



FIG. 4 shows the images captured by the first and second camera as the wire emerges from the aperture in the aperture plate.



FIG. 5 is a schematic showing the wire being pulled through the gelatin and water layers and through the aperture in the aperture plate.



FIG. 6 is a schematic showing a magnified view of a gelatin cone interacting with the aperture plate as the wire moves through the aperture plate.



FIG. 7 is a schematic showing an exploded view of a spool.



FIG. 8 is a schematic showing the final assembled spool.





DETAILED DESCRIPTION


FIG. 1 shows an embodiment of a system 100 of the invention for manufacturing a gelatin shunt. Device 100 includes a base 101 and a vertically extending shaft 102. There is a bath 103 at a junction of the base 101 and the shaft 102, such that the shaft 102 is aligned with the bath 103. The bath 103 can be any vessel configured to hold a liquid. In systems of the invention, the bath 103 holds the liquid gelatin and the water. The bath is operably connected to a temperature control unit 104. The temperature control unit 104 regulates the temperature of the bath 103, and any liquids within the bath 103. For making a shunt, the bath is maintained at about 55° C.


In particular embodiments, the bath 103 is a jacketed flask and the temperature control unit 104 is a water circulator with a heating component. The heater of the temperature control unit is set to a particular temperature, for example 55° C., which heats the water in the water circulator to the set temperature. The heated water is then circulated by the water circulator to the jacketed flask, which heats the flask, and its contents, to the temperature defined by the temperature control unit. Generally, the water level in the jacketed flask will be above the level of the gelatin inside the flask.


To the top of the bath 103 is affixed an aperture plate 105, i.e., a plate having an aperture 106 therethrough. The plate 105 is affixed to the bath 103 such that the aperture 106 is aligned with the shaft 102. An exemplary shaped aperture plate 105 is shown in FIG. 3. In this figure, the plate 105 has a base portion and a protruding portion affixed to the base. The aperture runs through the base and through the protruding portion.


System 100 includes a plurality of wheels 107a-107e. The wheels 107a-107e support a wire 108 and are arranged in a path that the wire 108 will travel. FIG. 2 is a magnified view of the system 100 shown in FIG. 1. FIG. 2 better shows the positioning of wheels 107a-107e and the path of travel of wire 108. Wheel 107a is mounted approximately halfway up the shaft 102. The exact position of wheel 107a on shaft 102 is not important and other positions of wheel 107a are envisioned for the systems of the invention. Wheel 107b is mounted on a support near the base 101 and is positioned to be directly below wheel 107a. Although, such exact positioning is not critical and wheel 107b may be placed in other places along the base. Wheel 107c is mounted at a top right edge of the bath 103. Wheel 107d is mounted at a bottom of bath 103. Wheel 107d is mounted such that it is in alignment with aperture 106 of aperture plate 105 and shaft 102. Wheel 107e is positioned at the top of shaft 102. The exact position of wheel 107e on shaft 102 is not important and other positions of wheel 107e are envisioned for the systems of the invention. Wheel 107f is mounted on a support near the base 101. Wheel 107f is operably coupled to stepper motor 109. An exemplary stepper motor is commercially available from Automation Direct (Cumming, Ga.).


The wheels 107a-107e are arranged such that when wire 108 is mounted on wheels 107a-107e, the wheels provide a constant tension for wire 108. Wire 108 is spooled on wheel 107a. Wire 108 is then run under wheel 107b, over wheel 107c, under wheel 107d, over wheel 107e, and spools again onto wheel 107f. The arrangement provides that wire 108 travels down into the base of bath 103, and makes a turn at the base of bath 103, such that after the turn, wire 108 travels vertically up through the bath 103, through the aperture 106 of the aperture plate 105, and vertically up the length of the shaft 102 to wheel 107e.


Stepper motor 109 in connection with wheel 107f drives movement of wire 108 and controls the speed at which wire 108 travels. The thickness of the walls of the formed shunt will depend on the speed at which the wire 108 is traveling. Increasing the pull speed will increase the diameter of the shunt, while decreasing the pull speed will decrease the diameter of the shunt. Stepper motor 109 is controlled by computer 114 and powered by DC power supply 115.


Wire 108 is preferably stainless steel, which may optionally be coated with a biocompatible, lubricious material such as polytetrafluoroethylene (Teflon). The coating helps in removing the dried gelatin shunt from the wire 108. The gauge of the wire will depend on the desired inner diameter of the shunt being produced. Generally, wires are used that produce a shunt having an inner diameter from approximately 10 μm to approximately 250 μm, preferably from about 40 μm to about 200 μm.


System 100 may include at least one camera for real time monitoring of the manufacturing of the shunt. FIGS. 1-2 show an embodiment that includes two cameras 110 and 111. Camera 110 monitors the wire 108 at the point that it is emerging from the aperture 106. Camera 111 is a high magnification camera that includes measurement software to allow for real time measurement of the thickness and diameter of the gelatin coating the wire 108 as it emerges from the aperture 106. Exemplary cameras are DINO-LITE cameras, commercially available from (AnMo Electronics Corporation, Torrance, Calif.). FIG. 4 shows the images captured by cameras 110 and 111. The top image is the image produced by camera 111, and the bottom image is the image produced by camera 110). Cameras 110 and 111 are operably coupled to computer 114, which controls the cameras.


System 100 also includes an ultrasonic fogger 112 coupled to a tube 113. The tube 113 runs most of the length of the shaft 102, extending from the top of the shaft 102 down to the top camera 111. The tube 113 is positioned such that the wire 108 passes into the tube 113 upon emerging from the aperture 106. The fogger 112 is positioned such that the produced fog enters the tube 113. The fog produced by the fogger 112 keeps the outer skin of the gelatin hydrated as the internal volume of the gelatin shrinks. An exemplary fogger is commercially available from Exo-terra (Mansfield, Mass.).


To make the gelatin shunt, the bath 103 is pre-heated to a temperature of about 55° C. During the pre-heating, the liquid gelatin 116 is made. In a certain embodiment, the gelatin used for making the shunt is known as gelatin Type B from bovine skin. An exemplary gelatin is PB Leiner gelatin from bovine skin, Type B, 225 Bloom, USP. Another material that may be used in the making of the shunt is a gelatin Type A from porcine skin, also available from Sigma Chemical. Such gelatin is available from Sigma Chemical Company of St. Louis, Mo. Under Code G-9382. Still other suitable gelatins include bovine bone gelatin, porcine bone gelatin and human-derived gelatins. In addition to gelatins, the flexible portion may be made of hydroxypropyl methylcellulose (HPMC), collagen, polylactic acid, polyglycolic acid, hyaluronic acid and glycosaminoglycans.


In an exemplary protocol, the gelatin solution is typically prepared by dissolving a gelatin powder in de-ionized water or sterile water for injection and placing the dissolved gelatin in a water bath at a temperature of approximately 55° C. with thorough mixing to ensure complete dissolution of the gelatin. In one embodiment, the ratio of solid gelatin to water is approximately 10% to 50% gelatin by weight to 50% to 90% by weight of water. In an embodiment, the gelatin solution includes approximately 40% by weight, gelatin dissolved in water. The resulting gelatin solution should be devoid of air bubbles and has a viscosity that is between approximately 200-500 cp and more particularly between approximately 260 and 410 cp (centipoise).



FIGS. 5 and 6 illustrate the process of the gelatin 116 being taken up the wire 108. Once prepared, the liquid gelatin 116 is poured into bath 103 that has been pre-heated to 55° C., thus maintaining the liquid gelatin at 55° C. After the gelatin 116 has been poured into the bath 103, a water layer 117 is added on top of the gelatin layer 116. The water envelops the aperture plate 105 such that a top surface of the plate 105 is submerged about 1 mm below the surface of water 117. The bottom of the plate 105 is positioned so that it does not touch the gelatin layer 116. Powered by stepper motor 109, the wire 108 is pulled down into the base of the bath 103 and then turns vertically up through the gelatin layer 116, the water layer 117, and the aperture 106 in the aperture plate 105. In this manner, the wire 108 becomes coated with gelatin 116 as it passes through the gelatin layer 116. Upon pulling the gelatin 116 through the water layer 117, a uniform cone 118 of gelatin 116 forms. Where the cone 118 intersects the water-air boundary, a spot forms. The cone 118 feeds into the aperture 106 in the aperture plate 105. The aperture 106 controls the gelatin 116 and the spot, such that the cone 118 of gelatin 116 that feeds the spot is consistent and yields a uniform uptake of gelatin 116 onto the wire 108.


The wire 108 then advances past cameras 110 and 111, which provide a real-time check of the thickness of the gelatin 116 that is being taken up the wire 108. Feedback from the camera can be used to adjust the speed of the wire 108, thus adjusting the thickness of the gelatin 116. Increasing the pull speed will increase the diameter of the shunt, while decreasing the pull speed will decrease the diameter of the shunt.


After passing the cameras, the gelatin-coated wire moves into tube 113 that is already being supplied with fog from fogger 112. The wire 108 is advanced until the wet gelatin 116 reaches the wheel 107e at the top of the shaft 102. The gelatin 116 on the wire 108 becomes immersed in the fog from fogger 112. The fogger is run for approximately 5-10 minutes after the gelatin-coated wire enters the fogger. The fogger is turned off and the gelatin is allowed to dry. Having the outer skin of the gelatin 116 in a humidity-controlled environment, keeps the skin of the gelatin 116 hydrated as an internal volume of the gelatin 116 shrinks. In this manner, a uniform implant is produced along the length of the wire 108.


The wire 108 is then cut below wheel 107e and above the top camera 111, using for example, stainless steel surgical sheers. The wire is cut into sections using the stainless steel surgical sheers to produce sections of a desired length. At this point, a cross-linking procedure can be performed on the gelatin. In one embodiment, the gelatin may be cross-linked by dipping the wire sections (with gelatin thereon) into the 25% glutaraldehyde solution, at pH of approximately 7.0-7.8 and more preferably approximately 7.35-7.44 at room temperature for at least 4 hours and preferably between approximately 10 to 36 hours, depending on the degree of cross-linking desired. In one embodiment, the gelatin is contacted with a cross-linking agent such as glutaraldehyde for at least approximately 16 hours. Cross-linking can also be accelerated when it is performed a high temperatures. It is believed that the degree of cross-linking is proportional to the bioabsorption time of the shunt once implanted. In general, the more cross-linking, the longer the survival of the shunt in the body.


The residual glutaraldehyde or other cross-linking agent is removed from the gelatin by soaking the tubes in a volume of sterile water for injection. The water may optionally be replaced at regular intervals, circulated or re-circulated to accelerate diffusion of the unbound glutaraldehyde from the gelatin. The gelatin is washed for a period of a few hours to a period of a few months with the ideal time being 3-14 days. The now cross-linked gelatin may then be dried (cured) at ambient temperature for a selected period of time. It has been observed that a drying period of approximately 48-96 hours and more typically 3 days (i.e., 72 hours) may be preferred for the formation of the cross-linked gelatin.


Where a cross-linking agent is used, it may be desirable to include a quenching agent. Quenching agents remove unbound molecules of the cross-linking agent from the gelatin. In certain cases, removing the cross-linking agent may reduce the potential toxicity to a patient if too much of the cross-linking agent is released from the gelatin. In certain embodiments, the gelatin is contacted with the quenching agent after the cross-linking treatment and, may be included with the washing/rinsing solution. Examples of quenching agents include glycine or sodium borohydride.


In certain embodiments, drug-coated/drug-impregnated shunts are produced. Shunts may be coated or impregnated with at least one pharmaceutical and/or biological agent or a combination thereof. Any pharmaceutical and/or biological agent or combination thereof may be used with shunts of the invention. The pharmaceutical and/or biological agent may be released over a short period of time (e.g., seconds) or may be released over longer periods of time (e.g., days, weeks, months, or even years). Exemplary agents include anti-mitotic pharmaceuticals such as Mitomycin-C or 5-Fluorouracil, anti-VEGF (such as Lucentis, Macugen, Avastin, VEGF or steroids). Exemplary agents are shown in Darouiche (U.S. Pat. Nos. 7,790,183; 6,719,991; 6,558,686; 6,162,487; 5,902,283; 5,853,745; and 5,624,704) and Yu et al. (U.S. patent application Ser. No. 2008/0108933). The content of each of these references is incorporated by reference herein its entirety.


In certain embodiments, an implant is produced with a thin layer of drug infused gelatin on an inside of the shunt. The thin inner layer will dissolve over time, thus delivering the drug. To produce such a shunt, the wire is pulled through a gelatin solution that has been infused with a drug to deposit a thin wall (e.g., 3-20 μm) of drug-infused gelatin on the wire. Alternatively, the wire is pulled through a gelatin solution that does not include a drug and the gelatin is instead soaked in the drug after it is pulled on the wire. In either case, the drug infused gelatin is then subjected to cross-linking with a controlled glutaraldehyde concentration for a controlled time to effect a non-permanent cross-linking that dissolves over time in tissue. Once this drug infused gelatin has been produced, the drug-infused gelatin is then pulled through the standard gelatin bath to coat the drug infused gelatin with a layer of gelatin that does not include a drug. This produces the final diameter of the shunt. The drug free layer of gelatin is then permanently cross-linked, thus producing a shunt with a thin layer of drug infused gelatin on an inside of the shunt.


In other embodiments, an implant is produced with a thin layer of drug infused gelatin on an outside of the shunt. The thin inner layer will dissolve over time, thus delivering the drug. To produce such a shunt, the wire is pulled through the standard gelatin solution in the bath to a diameter of about 3-50 μm smaller than the desired diameter of the final implant. This layer is permanently cross-linked. The gelatin-coated wire is then pulled through a drug infused gelatin solution to deposit a thin wall (e.g., 3-50 μm) onto the gelatin-coated wire. Alternatively, the wire is pulled through a gelatin solution that does not include a drug and the gelatin is instead soaked in the drug after it is pulled on the wire. In either case, the drug infused gelatin is then subjected to cross-linking with a controlled glutaraldehyde concentration for a controlled time to effect a non-permanent cross-linking that dissolves over time in tissue.


INCORPORATION BY REFERENCE

References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.


Equivalents

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.


EXAMPLES
Example 1
Gelatin Preparation

Into a 600 mL beaker was added 98±1 grams of porcine gelatin. An amount of about 172±1 grams of USP sterile water was measured and poured into the beaker containing the porcine gelatin. The beaker was sealed with parafilm, and the covered beaker was placed in a water bath at 55±1° C. for a minimum of 8 hours (maximum 36 hours). Ensure water level is higher than mixture in beaker. The lid of the water bath was checked to ensure that it was closed and after the minimum time period had elapsed, the beaker was removed from bath. The beaker was visually observed to verify that all gelatin in the mixture was dissolved and that mixture appeared homogeneous.


Example 2
Gelatin Transfer

The water circulator was checked to make sure that it was at a sufficient level (between the high and low marks). The circulator was set and run at 40.5° C. and allowed to come to temperature before proceeding to the next step. The gelatin mixture from Example 1 was poured into the jacketed beaker on a fixture so that the meniscus was about 20 mm from the top. Within 1 minute of adding the gelatin mixture, 60 cc's of USP sterile water was added above the gelatin surface using a syringe. The water was added slowly so as not to disturb the gelatin. The mixture was allowed to settle for minimum 30 min.


Example 3
System Set-Up

A spool was assembled onto an axle using parts as shown in FIG. 7. The final assembled spool is shown in FIG. 8. The M6 screw (Item 8) was finger tightened, and pinch bolt (Item 7) was fastened onto the mount. In order to increase the friction on the spool, the M6 screw (Item 8) was advanced approximately a ¼ turn. The wire was then threaded onto the spool, and the spool was slid up the shaft. The spindle assembly was lowered into the gelatin mixture, about 5 mm from the bottom of flask. The aperture plate was lowered into the water layer under a top surface was submerged about 1 mm below the surface of water. The bottom surface of the aperture plate was above the gelatin layer.


The first and second cameras were positioned on the shaft so as to properly view the wire as it emerged from the aperture in the aperture plate. The tube of the fogger assembly was lowered over the shaft until a bottom of the tube is positioned just above the second camera. In this position, a top of the tube was approximately 2 inches above the upper wheel on the shaft. The fogger was started, and the volume and velocity on the fogger was adjusted until the fog was barely visible flowing at the bottom of the tube. The computer was initiated and the images produced by the camera were checked to ensure proper positioning of the cameras. The cameras were focused until edges of the wire had sharp contrast.


Example 4
Shunt Manufacturing

The computer was used to initiate the stepper motor and begin pulling the wire. The initial pull speed was 8,000 rpm. The aperture was checked for dry gelatin, and any dried gelatin was cleared by grasping the wire above the top camera using a gloved hand and swirling the wire around lightly for a few seconds while monitoring the aperture cameras. The concentration of the gelatin on the wire was fine-tuned by monitoring the cameras. Turning the X-axis stage micrometer in the clockwise direction moved the wire to the right relative to the gelatin. Turning the Y-axis stage micrometer in the clockwise direction moved the wire to the left relative to the gelatin. Active measures of the gelatin thickness on the wire were taken. The total diameter of the gelatin in both the X and Y views was measured. The relative wall thickness of the gelatin on each side of the wire in both the X and Y views was obtained by measuring from the left edge of the gelatin to the left edge of the wire and from the right edge of the gelatin to the right edge of the wire. The pull speed was adjusted to achieve a target wet diameter of the gelatin.


Once the target wet diameter was achieved, the fixture was run until gelatin reached the upper wheel at the top of the shaft. The movement of the wire was stopped at this point. After terminating the movement of the wire, the fog from the fogger was allowed to continue to flow over the wire for a minimum of 5 additional minutes. After five minutes, the fogger was turned off and the gelatin was allowed to dry for a minimum of 3 additional minutes. The wire was then cut below the upper wheel and above the top camera using stainless steel surgical shears. The cut wire was then subsequently cut into 4-4.25 inch sections using stainless steel surgical shears and prepared for cross-linking. The individual sections were cross-linked. The shunts were then cut to a desired length (e.g., 2-20 mm), and each shunt was removed from the wire.

Claims
  • 1. A method for manufacturing a gelatin shunt, the method comprising: moving a wire through a first liquid bath to produce a first tubular layer of drug-infused gelatin;moving the wire through a second liquid bath to produce a second tubular layer of drug-free gelatin; andwhile exposing the gelatin coating to an ultrasonic water fog, drying the first and second tubular layers on the wire in a humidity-controlled space, thereby manufacturing a drug-loaded gelatin shunt.
  • 2. The method of claim 1, wherein the first tubular layer ranges between 3 μm and 20 μm in thickness.
  • 3. The method of claim 1, wherein the moving the wire through the first liquid bath is performed after moving the wire through the second liquid bath.
  • 4. The method of claim 1, wherein the wire comprises a drug-free gelatin layer, and moving the wire through the first liquid bath comprises soaking the drug into the drug-free gelatin layer to produce the first tubular layer of drug-infused gelatin.
  • 5. The method of claim 1, further comprising cross-linking the first tubular layer.
  • 6. The method of claim 5, wherein the cross-linking the first tubular layer occurs before the moving the wire through the second liquid bath.
  • 7. The method of claim 1, further comprising cross-linking the second tubular layer.
  • 8. The method of claim 7, wherein the cross-linking the second tubular layer occurs before the moving the wire through the first liquid bath.
  • 9. The method of claim 1, wherein the first liquid bath is infused with a drug.
  • 10. The method of claim 1, wherein the moving the wire through the first liquid bath comprises moving the wire through a drug-free liquid bath to produce a preformed layer and thereafter soaking the preformed layer in a drug to produce the first tubular layer.
  • 11. The method of claim 1, wherein the drug is selected from the group consisting of an anti-mitotic pharmaceutical, an anti-VEGF agent, a steroid, an antifibrotic agent, an antimicrobial agent, an antiseptic, and a time-release pharmaceutical or biological agent.
  • 12. The method of claim 1, wherein the drying the first and second tubular layers comprises drying the first tubular layer before the moving the wire through the second liquid bath.
  • 13. A method for manufacturing a gelatin shunt, the method comprising: moving a wire through a liquid bath to coat the wire with gelatin, thereby producing a gelatin-coated wire comprising a gelatin coating;while exposing the gelatin coating to an ultrasonic water fog, drying the gelatin coating on the wire in a humidity-controlled space, thereby manufacturing a gelatin shunt; and coating the gelatin shunt with a drug.
  • 14. The method of claim 13, further comprising: drawing the gelatin-coated wire through an aperture before drying the gelatin coating, thereby controlling a cross-sectional thickness of the gelatin coating.
  • 15. The method of claim 14, further comprising: cross-linking the gelatin coating after coating the gelatin shunt with the drug.
  • 16. The method of claim 14, wherein the drug is selected from the group consisting of an anti-mitotic pharmaceutical, an anti-VEGF agent, a steroid, an antifibrotic agent, an antimicrobial agent, an antiseptic, and a time-release pharmaceutical or biological agent.
  • 17. The method of claim 14, wherein coating the gelatin shunt comprises coating an exterior surface of the gelatin shunt with the drug.
  • 18. The method of claim 14, wherein the liquid bath comprises a top layer and a bottom layer, the top layer comprising water and the bottom layer comprising gelatin.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application a continuation of U.S. patent application Ser. No. 14/834,158, filed on Aug. 24, 2015, which is a continuation of U.S. patent application Ser. No. 14/295,020, filed on Jun. 3, 2014, now U.S. Pat. No. 9,113,994, which is a continuation of U.S. patent application Ser. No. 13/314,950, filed on Dec. 8, 2011, now U.S. Pat. No. 8,765,210, the entirety of each of which is incorporated herein by reference.

US Referenced Citations (288)
Number Name Date Kind
3788327 Donowitz et al. Jan 1974 A
3960150 Hussain et al. Jun 1976 A
4090530 Lange May 1978 A
4431688 Kornmann Feb 1984 A
4562463 Lipton Dec 1985 A
4583117 Lipton et al. Apr 1986 A
4722724 Schocket Feb 1988 A
4744362 Grundler May 1988 A
4750901 Molteno Jun 1988 A
4787885 Binder Nov 1988 A
4804382 Turina et al. Feb 1989 A
4820626 Williams et al. Apr 1989 A
4826478 Schocket May 1989 A
4848340 Bille et al. Jul 1989 A
4863457 Lee Sep 1989 A
4902292 Joseph Feb 1990 A
4911161 Schechter Mar 1990 A
4916684 MacKeen et al. Apr 1990 A
4934363 Smith et al. Jun 1990 A
4936825 Ungerleider Jun 1990 A
4946436 Smith Aug 1990 A
4968296 Ritch et al. Nov 1990 A
4978352 Fedorov et al. Dec 1990 A
5041081 Odrich Aug 1991 A
5057098 Zelman Oct 1991 A
5071408 Ahmed Dec 1991 A
5092837 Ritch et al. Mar 1992 A
5098426 Sklar et al. Mar 1992 A
5098443 Parel et al. Mar 1992 A
5162641 Fountain Nov 1992 A
5178604 Baerveldt et al. Jan 1993 A
5180362 Worst Jan 1993 A
5201750 Hocherl et al. Apr 1993 A
5275622 Lazarus et al. Jan 1994 A
5290295 Querals et al. Mar 1994 A
5300020 L'Esperance, Jr. Apr 1994 A
5338291 Speckman et al. Aug 1994 A
5342370 Simon et al. Aug 1994 A
5360339 Rosenberg Nov 1994 A
5368015 Wilk Nov 1994 A
5370607 Memmen Dec 1994 A
5399951 Lavallee et al. Mar 1995 A
5410638 Colgate et al. Apr 1995 A
5443505 Wong et al. Aug 1995 A
5476445 Baerveldt et al. Dec 1995 A
5516522 Peyman et al. May 1996 A
5520631 Nordquist et al. May 1996 A
5545206 Carson Aug 1996 A
5558629 Baerveldt et al. Sep 1996 A
5558630 Fisher Sep 1996 A
5601094 Reiss Feb 1997 A
5665093 Atkins et al. Sep 1997 A
5665114 Weadock et al. Sep 1997 A
5670161 Healy et al. Sep 1997 A
5688562 Hsiung Nov 1997 A
5695474 Daugherty Dec 1997 A
5704907 Nordquist et al. Jan 1998 A
5722948 Gross Mar 1998 A
5743868 Brown et al. Apr 1998 A
5763491 Brandt et al. Jun 1998 A
5868697 Richter et al. Feb 1999 A
5908449 Bruchman et al. Jun 1999 A
5928424 Krebs et al. Jul 1999 A
5932299 Katoot Aug 1999 A
6007511 Prywes Dec 1999 A
6007578 Schachar Dec 1999 A
6050970 Baerveldt Apr 2000 A
6102045 Nordquist et al. Aug 2000 A
6165210 Lau et al. Dec 2000 A
6203513 Yaron et al. Mar 2001 B1
6228873 Brandt et al. May 2001 B1
6261256 Ahmed Jul 2001 B1
6264665 Yu et al. Jul 2001 B1
6280468 Schachar Aug 2001 B1
6413540 Yaacobi Jul 2002 B1
6450937 Mercereau et al. Sep 2002 B1
6450984 Lynch et al. Sep 2002 B1
6464724 Lynch et al. Oct 2002 B1
6471666 Odrich Oct 2002 B1
6524275 Lynch et al. Feb 2003 B1
6533768 Hill Mar 2003 B1
6544249 Yu et al. Apr 2003 B1
6558342 Yaron et al. May 2003 B1
6595945 Brown Jul 2003 B2
6638239 Bergheim et al. Oct 2003 B1
6645183 Christensen et al. Nov 2003 B2
6666841 Gharib et al. Dec 2003 B2
6676998 Huang et al. Jan 2004 B2
6699210 Williams et al. Mar 2004 B2
6726664 Yaron et al. Apr 2004 B2
6730056 Ghaem et al. May 2004 B1
6736791 Tu et al. May 2004 B1
6881198 Brown Apr 2005 B2
6939298 Brown et al. Sep 2005 B2
7008396 Straub Mar 2006 B1
7037335 Freeman et al. May 2006 B2
7041077 Shields May 2006 B2
7094225 Tu et al. Aug 2006 B2
7118547 Dahan Oct 2006 B2
7135009 Tu et al. Nov 2006 B2
7163543 Smedley et al. Jan 2007 B2
7186232 Smedey et al. Mar 2007 B1
7192412 Zhou et al. Mar 2007 B1
7207980 Christian et al. Apr 2007 B2
7291125 Coroneo Nov 2007 B2
7297154 Tu et al. Nov 2007 B2
7331984 Tu et al. Feb 2008 B2
7344528 Tu et al. Mar 2008 B1
7431709 Pinchuk et al. Oct 2008 B2
7431710 Tu et al. Oct 2008 B2
7458953 Peyman Dec 2008 B2
7488303 Haffner et al. Feb 2009 B1
7524298 Gharib et al. Apr 2009 B2
7594899 Pinchuk et al. Sep 2009 B2
7625384 Eriksson et al. Dec 2009 B2
7678065 Haffner et al. Mar 2010 B2
7708711 Tu et al. May 2010 B2
7717872 Shetty May 2010 B2
7740604 Schieber et al. Jun 2010 B2
7794437 Humayun et al. Sep 2010 B2
7837644 Pinchuk et al. Nov 2010 B2
7862531 Yaron et al. Jan 2011 B2
7867186 Haffner et al. Jan 2011 B2
7998497 de Juan, Jr. et al. Aug 2011 B2
8003124 Varner et al. Aug 2011 B2
8109896 Nissan et al. Feb 2012 B2
8267882 Euteneuer et al. Sep 2012 B2
8277437 Saal et al. Oct 2012 B2
8308701 Horvath et al. Nov 2012 B2
8313454 Yaron et al. Nov 2012 B2
8337393 Silverstrini et al. Dec 2012 B2
8337509 Schieber et al. Dec 2012 B2
8377122 Silvestrini et al. Feb 2013 B2
8425449 Wardle et al. Apr 2013 B2
8444589 Silvestrini May 2013 B2
8486000 Coroneo Jul 2013 B2
8506515 Burns et al. Aug 2013 B2
8512404 Frion et al. Aug 2013 B2
8529492 Clauson et al. Sep 2013 B2
8535333 de Juan, Jr. et al. Sep 2013 B2
8545430 Silvestrini Oct 2013 B2
8585629 Grabner et al. Nov 2013 B2
8663303 Horvath et al. Mar 2014 B2
8721702 Romoda et al. May 2014 B2
8758290 Horvath et al. Jun 2014 B2
8765210 Romoda et al. Jul 2014 B2
8801766 Reitsamer et al. Aug 2014 B2
8828070 Romoda et al. Sep 2014 B2
8852136 Horvath et al. Oct 2014 B2
8852137 Horvath et al. Oct 2014 B2
8852256 Horvath et al. Oct 2014 B2
8974511 Horvath et al. Mar 2015 B2
9017276 Horvath et al. Apr 2015 B2
9044301 Pinchuk et al. Jun 2015 B1
9095411 Horvath et al. Aug 2015 B2
9095413 Romoda et al. Aug 2015 B2
9113994 Romoda et al. Aug 2015 B2
9125723 Horvath et al. Sep 2015 B2
20020099434 Buscemi et al. Jul 2002 A1
20020133168 Smedley et al. Sep 2002 A1
20020143284 Tu et al. Oct 2002 A1
20030015203 Makower et al. Jan 2003 A1
20030055372 Lynch et al. Mar 2003 A1
20030060752 Bergheim et al. Mar 2003 A1
20030097053 Itoh May 2003 A1
20030097151 Smedley et al. May 2003 A1
20030229303 Haffner et al. Dec 2003 A1
20030236483 Ren Dec 2003 A1
20030236484 Lynch et al. Dec 2003 A1
20040024345 Gharib et al. Feb 2004 A1
20040077987 Rapacki et al. Apr 2004 A1
20040111050 Smedley et al. Jun 2004 A1
20040147870 Burns et al. Jul 2004 A1
20040154946 Solovay et al. Aug 2004 A1
20040210209 Yeung et al. Oct 2004 A1
20040216749 Tu Nov 2004 A1
20040225250 Yablonski Nov 2004 A1
20040254521 Simon Dec 2004 A1
20040260227 Lisk et al. Dec 2004 A1
20050049578 Tu et al. Mar 2005 A1
20050101967 Weber et al. May 2005 A1
20050119601 Lynch et al. Jun 2005 A9
20050143363 De Juan et al. Jun 2005 A1
20050246023 Yeung Nov 2005 A1
20050250788 Tu et al. Nov 2005 A1
20050261624 Wilcox Nov 2005 A1
20050267398 Protopsaltis et al. Dec 2005 A1
20050271704 Tu et al. Dec 2005 A1
20050277864 Haffner et al. Dec 2005 A1
20060032507 Tu Feb 2006 A1
20060106370 Baerveldt et al. May 2006 A1
20060110428 deJuan et al. May 2006 A1
20060116625 Renati et al. Jun 2006 A1
20060147643 Volkov et al. Jul 2006 A1
20060149194 Conston et al. Jul 2006 A1
20060155238 Shields Jul 2006 A1
20060173397 Tu et al. Aug 2006 A1
20060173446 Dacquay et al. Aug 2006 A1
20060200113 Haffner et al. Sep 2006 A1
20070027537 Castillejos Feb 2007 A1
20070118065 Pinchuk et al. May 2007 A1
20070141116 Pinchuk et al. Jun 2007 A1
20070172903 Toner et al. Jul 2007 A1
20070191863 De Juan et al. Aug 2007 A1
20070233037 Gifford et al. Oct 2007 A1
20070269487 de Juan et al. Nov 2007 A1
20070293807 Lynch et al. Dec 2007 A1
20070293872 Peyman Dec 2007 A1
20080057106 Erickson et al. Mar 2008 A1
20080108933 Yu May 2008 A1
20080147001 Al-Marashi et al. Jun 2008 A1
20080181929 Robinson et al. Jul 2008 A1
20080281277 Thyzel Nov 2008 A1
20080312661 Downer et al. Dec 2008 A1
20090036818 Grahn et al. Feb 2009 A1
20090043321 Conston et al. Feb 2009 A1
20090082860 Schieber et al. Mar 2009 A1
20090082862 Schieber et al. Mar 2009 A1
20090099626 de Juan, Jr. et al. Apr 2009 A1
20090104243 Utkhede et al. Apr 2009 A1
20090177138 Brown et al. Jul 2009 A1
20090182421 Silvestrini et al. Jul 2009 A1
20090209910 Kugler et al. Aug 2009 A1
20090287136 Castillejos Nov 2009 A1
20100098772 Robinson et al. Apr 2010 A1
20100100104 Yu et al. Apr 2010 A1
20100114006 Baerveldt May 2010 A1
20100119696 Yu et al. May 2010 A1
20100121248 Yu et al. May 2010 A1
20100121249 Yu et al. May 2010 A1
20100134759 Silvestrini et al. Jun 2010 A1
20100137981 Silvestrini et al. Jun 2010 A1
20100191103 Stamper et al. Jul 2010 A1
20100241046 Pinchuk et al. Sep 2010 A1
20100249691 Van Der Mooren et al. Sep 2010 A1
20110046536 Stegmann et al. Feb 2011 A1
20110098627 Wilcox Apr 2011 A1
20110098809 Wardle et al. Apr 2011 A1
20110105986 Bronstein et al. May 2011 A1
20110105990 Silvestrini May 2011 A1
20110118745 Yu et al. May 2011 A1
20110118835 Silvestrini et al. May 2011 A1
20110230890 Thyzel Sep 2011 A1
20110234976 Kocaoglu et al. Sep 2011 A1
20110319806 Wardle Dec 2011 A1
20120078362 Haffner et al. Mar 2012 A1
20120123315 Horvath et al. May 2012 A1
20120123316 Horvath et al. May 2012 A1
20120123317 Horvath et al. May 2012 A1
20120123434 Grabner et al. May 2012 A1
20120165720 Horvath et al. Jun 2012 A1
20120165933 Haffner et al. Jun 2012 A1
20120197175 Horvath et al. Aug 2012 A1
20120226150 Balicki et al. Sep 2012 A1
20120310137 Silvestrini Dec 2012 A1
20120323159 Wardle et al. Dec 2012 A1
20130150773 Nissan et al. Jun 2013 A1
20130184631 Pinchuk Jul 2013 A1
20130245573 de Juan, Jr. et al. Sep 2013 A1
20130253528 Haffner et al. Sep 2013 A1
20130281817 Schaller et al. Oct 2013 A1
20130281907 Wardle et al. Oct 2013 A1
20130289467 Haffner et al. Oct 2013 A1
20130325024 Nissan et al. Dec 2013 A1
20140066833 Yaron et al. Mar 2014 A1
20140081195 Clauson et al. Mar 2014 A1
20140135916 Clauson et al. May 2014 A1
20140163448 Lind et al. Jun 2014 A1
20140213958 Clauson et al. Jul 2014 A1
20140236066 Horvath et al. Aug 2014 A1
20140243730 Horvath Aug 2014 A1
20140275923 Haffner et al. Sep 2014 A1
20140276332 Crimaldi et al. Sep 2014 A1
20140303544 Haffner et al. Oct 2014 A1
20140323995 Clauson et al. Oct 2014 A1
20140364789 Schaller Dec 2014 A1
20150005689 Horvath et al. Jan 2015 A1
20150011926 Reitsamer et al. Jan 2015 A1
20150038893 Haffner et al. Feb 2015 A1
20150133946 Horvath et al. May 2015 A1
20150290035 Horvath et al. Oct 2015 A1
20150374545 Horvath et al. Dec 2015 A1
20160135993 Horvath et al. May 2016 A1
20160135994 Romoda et al. May 2016 A1
20160158063 Romoda et al. Jun 2016 A1
20160256321 Horvath et al. Sep 2016 A1
20160256322 Horvath et al. Sep 2016 A1
20170172800 Romoda et al. Jun 2017 A1
Foreign Referenced Citations (7)
Number Date Country
2 296 663 Jul 1996 GB
WO-9823237 Jun 1998 WO
WO-2000056255 Sep 2000 WO
WO-200274052 Sep 2002 WO
WO-2007087061 Aug 2007 WO
WO-2008005873 Jan 2008 WO
WO-2017040855 Mar 2017 WO
Non-Patent Literature Citations (1)
Entry
QUERE, “Fluid Coating on a Fiber,” Annu. Rev. Fluid Mech. 1999, 31:347-84.
Related Publications (1)
Number Date Country
20170172800 A1 Jun 2017 US
Continuations (3)
Number Date Country
Parent 14834158 Aug 2015 US
Child 15454945 US
Parent 14295020 Jun 2014 US
Child 14834158 US
Parent 13314950 Dec 2011 US
Child 14295020 US